Literature DB >> 7783875

Blood-brain barrier disruption on contrast-enhanced MRI in patients with mild relapsing-remitting multiple sclerosis: relationship to course, gender, and age.

L A Stone1, M E Smith, P S Albert, C N Bash, H Maloni, J A Frank, H F McFarland.   

Abstract

MRI has provided insight into the pathophysiology and course of MS, particularly through the use of a paramagnetic contrast agent that allows visualization of blood-brain barrier (BBB) breakdown. Neither the overall frequency of BBB breakdown in MS patients nor the characteristics associated with BBB breakdown in MS are known. We studied 68 relapsing-remitting MS (RRMS) patients with three monthly MRIs to examine these questions. Seventy-eight percent of the RRMS patients studied had evidence of BBB breakdown on at least one MRI. While there was a great deal of variability among patients in terms of mean enhancing lesion frequency, BBB breakdown was associated with younger age at onset of disease, measured by age at first symptom or age at diagnosis, and more severe disease as measured by Expanded Disability Status Scale scores equal to or greater than 4.0. We found no relationship between BBB breakdown and duration of disease or gender. We conclude that BBB breakdown is a relatively common phenomenon in RRMS patients and may be most commonly found in patients with more aggressive disease and younger onset. These findings have implications for clinical trials that use MRI as an outcome measure.

Entities:  

Mesh:

Year:  1995        PMID: 7783875     DOI: 10.1212/wnl.45.6.1122

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  24 in total

1.  Luteolin inhibits myelin basic protein-induced human mast cell activation and mast cell-dependent stimulation of Jurkat T cells.

Authors:  D Kempuraj; M Tagen; B P Iliopoulou; A Clemons; M Vasiadi; W Boucher; M House; A Wolfberg; T C Theoharides
Journal:  Br J Pharmacol       Date:  2008-09-22       Impact factor: 8.739

Review 2.  More immunotherapy for multiple sclerosis.

Authors:  R A Hughes; B Sharrack
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-09       Impact factor: 10.154

3.  Exploratory treatment trials in multiple sclerosis using MRI: sample size calculations for relapsing-remitting and secondary progressive subgroups using placebo controlled parallel groups.

Authors:  N Tubridy; H J Ader; F Barkhof; A J Thompson; D H Miller
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-01       Impact factor: 10.154

Review 4.  Magnetic resonance in monitoring the natural history of multiple sclerosis and the effects of treatment.

Authors:  M Filippi; M Rovaris; G Comi
Journal:  Ital J Neurol Sci       Date:  1996-12

5.  Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria.

Authors:  G Edan; D Miller; M Clanet; C Confavreux; O Lyon-Caen; C Lubetzki; B Brochet; I Berry; Y Rolland; J C Froment; E Cabanis; M T Iba-Zizen; J M Gandon; H M Lai; I Moseley; O Sabouraud
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-02       Impact factor: 10.154

6.  Peptide derived from HIV-1 TAT protein destabilizes a monolayer of endothelial cells in an in vitro model of the blood-brain barrier and allows permeation of high molecular weight proteins.

Authors:  Itzik Cooper; Keren Sasson; Vivian I Teichberg; Michal Schnaider-Beeri; Mati Fridkin; Yoram Shechter
Journal:  J Biol Chem       Date:  2012-11-13       Impact factor: 5.157

Review 7.  TGF-β regulation of encephalitogenic and regulatory T cells in multiple sclerosis.

Authors:  Priscilla W Lee; Mary E Severin; Amy E Lovett-Racke
Journal:  Eur J Immunol       Date:  2017-02-10       Impact factor: 5.532

Review 8.  Sex-related factors in multiple sclerosis susceptibility and progression.

Authors:  Rhonda R Voskuhl; Stefan M Gold
Journal:  Nat Rev Neurol       Date:  2012-03-27       Impact factor: 42.937

9.  Identifying the start of multiple sclerosis injury: a serial DTI study.

Authors:  Daniel Ontaneda; Ken Sakaie; Jian Lin; Xiaofeng Wang; Mark J Lowe; Michael D Phillips; Robert J Fox
Journal:  J Neuroimaging       Date:  2014-02-23       Impact factor: 2.486

10.  Treatment of refractory epilepsy with natalizumab in a patient with multiple sclerosis. Case report.

Authors:  Stefano Sotgiu; Maria R Murrighile; Gabriela Constantin
Journal:  BMC Neurol       Date:  2010-09-23       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.